Short-Term Debt to Equity Ratio: Tevogen Bio Holdings (TVGN)
Tevogen Bio Holdings (TVGN) specializes in developing cell-based therapies to combat infections and brain pathologies, yet the business relies critically on new share issuances due to a lack of sales. How stable are the cash flows? Currently, their predictability is zero, and the 0.00 metric confirms a dependence on investments. This chart of share price action clearly illustrates the market reaction to these risks. Meanwhile, the company is integrating ESG principles into its research and strictly adhering to bioethics.
Comprehensive metric breakdowns and analytics for tevogen.com (TVGN)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
- company profitability and valuation multiples indicators:
Analysis of all company metrics:Tevogen Bio Holdings, Inc. TVGN
Tevogen Bio Holdings focuses on the clinical deployment of its T-cell platform through scientific partnerships. Analyzing the ratio of loans under one year to equity, an investor sees the current metric level of 0.00. This indicator measures the share of short-term liabilities within the equity structure to assess the risk of cash flow gaps. A steady decline in this ratio confirms the biotech's financial stability during a period of intensive research.
Competing companies
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|Short-Term Debt to Equity Ratio CPRX|DNLI (denalitherapeutics.com) - Short-Term Loans to Capital Ratio|Short-Term Debt to Capital HRMY|BHVN - Current Liabilities to Capital|Amylyx - Short-Term Debt to Equity Ratio|Trevi Corp - Short-Term Debt to Equity|PRAX - Short-Term Debt to Equity|Current Liabilities to Capital anavex.com|CBLL: Short-Term Debt to Capital|Short-Term Indebtedness to Equity Prothena Biosciences PRTA|ALEC (Alector Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital Annexon Biosciences Inc. ANNX|Short-Term Debt to Equity Omeros Corporation (OMER)|neurogene.com - Short-Term Debt to Capital Ratio|AC Immune SA - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital VYGR|Neumora Therapeutics Inc - Short-Term Debt to Capital|SCLX: Short-Term Debt to Equity|ACOG: Short-Term Debt to Capital|CGTX - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Inhibikase Therapeutics, Inc.|Current Liabilities to Capital Cassava Sciences Inc SAVA|Short-Term Debt to Equity Ratio ASRT (Assertio Holdings, Inc.)|COYA (coyatherapeutics.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital VTGN (Vistagen)|Ratio of Short-Term Indebtedness to Capital OVID|ABOS - Short-Term Debt to Equity|Current Liabilities to Capital CervoMed, Inc.|alteritytherapeutics.com (ATHE) - Short-Term Debt to Equity|CLNN (Clene) - Short-Term Debt to Equity|PEPG (PepGen Inc) - Short-Term Debt to Capital|Short-Term Debt to Capital Ratio JUNS (jupiterneurosciences.com)|Short-Term Debt to Capital RLMD|Short-Term Debt to Capital Coefficient Annovis Bio Inc|Short-Term Debt to Equity Grace Therapeutics GRCE|AIFF: Short-Term Debt to Capital Ratio|ANEW Medical, Inc. - Short-Term Debt to Capital|Short-Term Indebtedness to Equity NeuroSense Therapeutics (NRSN)|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Short-Term Debt to Equity|MTVA - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio NRXS|HSDT (Helius Medical Technologies Inc.) - Short-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio PASG (Passage Bio, Inc.)|Short-Term Debt to Equity NEUP (bionomics.com.au)|Short-Term Debt to Capital NERV (Minerva Neurosciences, Inc.)|Short-Term Indebtedness to Equity Athira Pharma Inc|ADXN - Short-Term Debt to Equity|ALZN (Alzamend Neuro, Inc.) - Short-Term Debt to Capital Ratio|cyclerion.com (CYCN) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio PTIX|KTTA (Pasithea Therapeutics Corp) - Short-Term Debt to Capital|Current Liabilities to Capital Cortigent Medical CRGT|Short-Term Debt to Equity Ratio ATXI (Avenue Therapeutics, Inc)|Short-Term Debt to Capital BrainStorm Cell Therapeutics Inc. (BCLI)|Short-Term Debt to Equity Cara Therapeutics, Inc. CARA|Ratio of Short-Term Indebtedness to Capital CHRO|ELYM - Short-Term Debt to Equity|Current Liabilities to Capital Intra-Cellular Therapies|LBPH (Longboard Pharma) - Short-Term Debt to Equity Ratio|MRNS: Short-Term Loans to Capital Ratio|NKGN (NKGen Biotech, Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital neurobopharma.com NRBO|Short-Term Debt to Equity Ratio SAGE (Sage Therapeutics)|Short-Term Debt to Equity SNPX (Synaptogenix Inc.)|Short-Term Debt to Equity Trevena, Inc TRVN|Vigil Neuroscience Inc. (VIGL) - Current Liabilities to Capital|Anew Medical, Inc. - Short-Term Debt to Capital|Short-Term Indebtedness to Equity cerevel.com (CERE)